EA200702169A1 - Профилактика вич-инфекции - Google Patents

Профилактика вич-инфекции

Info

Publication number
EA200702169A1
EA200702169A1 EA200702169A EA200702169A EA200702169A1 EA 200702169 A1 EA200702169 A1 EA 200702169A1 EA 200702169 A EA200702169 A EA 200702169A EA 200702169 A EA200702169 A EA 200702169A EA 200702169 A1 EA200702169 A1 EA 200702169A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv prevention
hiv infection
composition
long
hiv
Prior art date
Application number
EA200702169A
Other languages
English (en)
Other versions
EA011420B1 (ru
Inventor
Ливен Элвире Колетт Барт
Паулюс Йоханнес Леви
Ян Херес
Original Assignee
Тиботек Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиботек Фармасьютикалз Лтд. filed Critical Тиботек Фармасьютикалз Лтд.
Publication of EA200702169A1 publication Critical patent/EA200702169A1/ru
Publication of EA011420B1 publication Critical patent/EA011420B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Это изобретение относится к применению парентеральной композиции, включающей NNRTI TMC278 для длительной профилактики ВИЧ-инфекции у субъекта, имеющего риск инфицирования ВИЧ, которое включает периодическое введение упомянутой композиции через длительные интервалы времени.
EA200702169A 2005-04-04 2006-04-04 Профилактика вич-инфекции EA011420B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102616 2005-04-04
PCT/EP2006/061303 WO2006106103A2 (en) 2005-04-04 2006-04-04 Prevention of hiv- infection with tmc278

Publications (2)

Publication Number Publication Date
EA200702169A1 true EA200702169A1 (ru) 2008-02-28
EA011420B1 EA011420B1 (ru) 2009-02-27

Family

ID=34939113

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702169A EA011420B1 (ru) 2005-04-04 2006-04-04 Профилактика вич-инфекции

Country Status (29)

Country Link
US (6) US20080194601A1 (ru)
EP (1) EP1881848B1 (ru)
JP (2) JP5632579B2 (ru)
KR (1) KR101360851B1 (ru)
CN (2) CN103860560A (ru)
AP (1) AP2617A (ru)
AR (1) AR053571A1 (ru)
AU (1) AU2006231585B2 (ru)
BR (1) BRPI0607649B8 (ru)
CA (1) CA2602231C (ru)
CY (1) CY1113950T1 (ru)
DK (1) DK1881848T3 (ru)
EA (1) EA011420B1 (ru)
ES (1) ES2402864T3 (ru)
HK (2) HK1117039A1 (ru)
HR (1) HRP20130296T1 (ru)
IL (1) IL184744A (ru)
ME (1) ME01517B (ru)
MX (1) MX2007012277A (ru)
MY (1) MY150091A (ru)
NZ (1) NZ556659A (ru)
PL (1) PL1881848T3 (ru)
PT (1) PT1881848E (ru)
RS (1) RS52724B (ru)
SI (1) SI1881848T1 (ru)
TW (2) TW201414495A (ru)
UA (1) UA90124C2 (ru)
WO (1) WO2006106103A2 (ru)
ZA (1) ZA200708454B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
BR122020011487B1 (pt) * 2006-06-23 2024-02-20 Janssen Sciences Ireland Uc Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
SG196774A1 (en) * 2008-12-24 2014-02-13 Tibotec Pharm Ltd Implantable devices for treating hiv
KR101798430B1 (ko) 2009-12-21 2017-11-16 얀센 사이언시즈 아일랜드 유씨 활성 화합물의 서방출을 위한 분해 및 제거가능한 임플란트
DE102011082871A1 (de) * 2011-09-16 2013-03-21 Florian, Prof. Dr. Lang Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
WO2014093941A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Pharmaceutical compositions
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
IL151475A0 (en) 2000-03-30 2003-04-10 Bristol Myers Squibb Co Beadlets containing stavudine
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2004043433A2 (en) 2002-11-08 2004-05-27 Glaxo Group Limited Pharmaceutical antiviral compositions
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
CA2513527C (en) 2003-02-07 2012-08-14 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of hiv infection
AU2004212786A1 (en) 2003-02-21 2004-09-02 Tripep Ab Glycinamide derivative for inhibiting HIV replication
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
BR122020011487B1 (pt) * 2006-06-23 2024-02-20 Janssen Sciences Ireland Uc Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação

Also Published As

Publication number Publication date
BRPI0607649A2 (pt) 2009-09-22
BRPI0607649B1 (pt) 2019-08-06
AU2006231585A1 (en) 2006-10-12
HRP20130296T1 (hr) 2013-04-30
TW200709818A (en) 2007-03-16
US20080194601A1 (en) 2008-08-14
EP1881848B1 (en) 2013-01-16
AP2007004178A0 (en) 2007-10-31
SI1881848T1 (sl) 2013-05-31
RS52724B (en) 2013-08-30
US20220071997A1 (en) 2022-03-10
US20160151276A1 (en) 2016-06-02
EA011420B1 (ru) 2009-02-27
US20110077261A1 (en) 2011-03-31
CY1113950T1 (el) 2016-07-27
KR20080009051A (ko) 2008-01-24
US20160296519A1 (en) 2016-10-13
JP2013079275A (ja) 2013-05-02
MX2007012277A (es) 2007-10-17
HK1117039A1 (en) 2009-01-09
ME01517B (me) 2014-04-20
ES2402864T3 (es) 2013-05-09
KR101360851B1 (ko) 2014-02-11
AR053571A1 (es) 2007-05-09
CN101155599A (zh) 2008-04-02
CN103860560A (zh) 2014-06-18
CA2602231A1 (en) 2006-10-12
TWI457136B (zh) 2014-10-21
WO2006106103A3 (en) 2007-06-07
AU2006231585B2 (en) 2012-02-02
US20200397783A1 (en) 2020-12-24
DK1881848T3 (da) 2013-04-15
AP2617A (en) 2013-03-18
PT1881848E (pt) 2013-04-15
PL1881848T3 (pl) 2013-06-28
ZA200708454B (en) 2009-03-25
CA2602231C (en) 2014-03-25
TW201414495A (zh) 2014-04-16
JP5632579B2 (ja) 2014-11-26
IL184744A0 (en) 2007-12-03
HK1198936A1 (en) 2015-06-19
BRPI0607649B8 (pt) 2021-05-25
IL184744A (en) 2015-05-31
WO2006106103A2 (en) 2006-10-12
JP2008534651A (ja) 2008-08-28
NZ556659A (en) 2012-03-30
EP1881848A2 (en) 2008-01-30
UA90124C2 (ru) 2010-04-12
US10765674B2 (en) 2020-09-08
MY150091A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
EA200702169A1 (ru) Профилактика вич-инфекции
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
DK2110104T3 (da) Skinne med digital dorsalfleksion til natbrug
EA200401494A1 (ru) Бактерицидные пиримидины или триазины для профилактики передачи вич половым путём
ATE482953T1 (de) Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
TW200626559A (en) Anilino-pyrimidine analogs
EA201070786A1 (ru) Бензофуропиримидиноны
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
DK2203439T3 (da) 1',3'-disubstituerede 4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']-bipyridinyl-2'-oner
EA200802247A1 (ru) Схема дозирования кладрибина для лечения рассеянного склероза
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
BR112014030755A2 (pt) composições de intensificação de culturas
EA201290229A1 (ru) Производные спиролактама и их применение
EP2183256A4 (en) THERAPEUTIC COMPOUNDS
DE602008002598D1 (en) Cyclohexylderivate
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent